Summary
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death.
NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism. We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation.
NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway
NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism. We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation.
NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101188579 |
| Start date: | 01-02-2025 |
| End date: | 31-07-2026 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death.NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism. We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation.
NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway
Status
SIGNEDCall topic
ERC-2024-POCUpdate Date
21-11-2024
Images
No images available.
Geographical location(s)
